Moneycontrol
HomeNewsBusinessEconomyNew Development Bank should enhance emergency facility to $10 billion: FM Sitharaman

New Development Bank should enhance emergency facility to $10 billion: FM Sitharaman

Sitharaman mentioned about Prime Minister Narendra Modi's initiative of creating a COVID-19 Emergency Fund and India's efforts in supplying critical medicine to the needy countries to tackle the COVID-19, an official statement said.

April 20, 2020 / 23:16 IST
Story continues below Advertisement

Finance Minister Nirmala Sitharaman on Monday asked the New Development Bank (NDB) to enhance emergency facility to $10 billion to deal with the challenges posed by the outbreak of COVID-19 pandemic. During discussion on COVID-19 at the 5th Annual meeting of the Board of Governors of the NDB through video conferencing, Sitharaman appreciated the efforts of the multilateral lending agency on fast tracking of financial assistance of about $5 billion to BRICS countries, including an emergency assistance of $1 billion to India to combat COVID-19 pandemic.

"I am happy to note that the bank has financial capacity to enhance the emergency facility up to $10 billion for crisis related assistance. Therefore, based on the demands from the member countries this facility should be enhanced," she said.

Story continues below Advertisement

She mentioned about Prime Minister Narendra Modi's initiative of creating a COVID-19 Emergency Fund and India's efforts in supplying critical medicine to the needy countries to tackle the COVID-19, an official statement said.

The Finance Minister of Brazil thanked India for the timely help it received from India in the form of critical drugs, it added.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show